Diamyd Medical AB - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Diamyd Medical AB Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Diamyd Medical AB. The Group's primary activity is the development of medicine for diabetes. The Group operates in two segments: GAD technology and NTDDS technology. The GAD technology segment comprises of GAD-protein and Diamyd anti-GAD RIA-kits. The products are sold to researchers and laboratories. The NTDDS segment include the Group's first drug candidate from theNerve Targeting Drug Delivery System (NTDDS) gene therapy platform. The Group operates globally.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report